MUFG Securities EMEA plc Boosts Stock Position in Boston Scientific Corporation $BSX

MUFG Securities EMEA plc lifted its position in Boston Scientific Corporation (NYSE:BSX) by 1,096.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 339,427 shares of the medical equipment provider’s stock after purchasing an additional 311,065 shares during the quarter. MUFG Securities EMEA plc’s holdings in Boston Scientific were worth $32,364,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Forsta AP Fonden boosted its holdings in shares of Boston Scientific by 2.5% in the 4th quarter. Forsta AP Fonden now owns 375,200 shares of the medical equipment provider’s stock worth $35,775,000 after purchasing an additional 9,100 shares in the last quarter. Norges Bank purchased a new position in shares of Boston Scientific in the 4th quarter worth about $2,199,395,000. Eurizon Capital SGR S.p.A. purchased a new position in shares of Boston Scientific in the 4th quarter worth about $123,890,000. Fideuram Asset Management Ireland dac purchased a new position in shares of Boston Scientific in the 4th quarter worth about $3,118,000. Finally, National Pension Service boosted its holdings in shares of Boston Scientific by 8.6% in the 4th quarter. National Pension Service now owns 3,761,615 shares of the medical equipment provider’s stock worth $358,670,000 after purchasing an additional 296,409 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus acquired 1,770 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares in the company, valued at $99,987.30. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction on Wednesday, May 20th. The stock was acquired at an average price of $56.68 per share, with a total value of $202,914.40. Following the acquisition, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Trading Down 1.6%

Shares of BSX stock opened at $48.32 on Friday. The stock has a market capitalization of $71.82 billion, a PE ratio of 20.22, a P/E/G ratio of 0.89 and a beta of 0.62. Boston Scientific Corporation has a 1-year low of $48.13 and a 1-year high of $109.50. The business has a 50-day moving average of $60.23 and a 200 day moving average of $78.62. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts anticipate that Boston Scientific Corporation will post 3.37 earnings per share for the current year.

Boston Scientific announced that its board has authorized a stock repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Wells Fargo downgraded Boston Scientific to Equal Weight/hold and lowered its outlook on the stock, citing rising uncertainty around the company’s electrophysiology business and WATCHMAN growth. Wells Fargo cuts Boston Scientific to ’Equal Weight’ on Watchman slowdown
• Negative Sentiment: Reuters reported Boston Scientific hit a two-year low after flagging weaker demand for its WATCHMAN heart device, adding to investor concern that a core growth driver is slowing. Boston Scientific hits two-year low after flagging weaker demand for heart device
• Negative Sentiment: The company’s 2026 guidance was reiterated, but investors viewed it as underwhelming given the slowdown in WATCHMAN and softer urology demand, which hurt sentiment further. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
• Negative Sentiment: Analyst commentary from Zacks said Boston Scientific and Abbott both posted solid growth, but Boston Scientific is facing mounting operational pressures, which may be limiting upside near term. BSX vs. ABT: Which Medical Stock Has More Upside Potential?
• Positive Sentiment: Despite the selloff, Boston Scientific’s clinical pipeline remains active, with updates on the FARAPULSE PFA atrial fibrillation study and a painful diabetic neuropathy trial milestone that could support future growth. Boston Scientific Advances FARAPULSE PFA Study in Atrial Fibrillation Boston Scientific Nears Key Data Milestone in Painful Diabetic Neuropathy Trial
• Positive Sentiment: Unusually large call-option buying suggests some traders are positioning for a rebound in BSX after the recent weakness. Investors Buy Large Volume of Call Options on Boston Scientific (NYSE:BSX)

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Leerink Partners cut their price objective on Boston Scientific from $87.00 to $74.00 and set an “outperform” rating for the company in a report on Thursday. Citigroup cut their price objective on Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a report on Thursday. Canaccord Genuity Group dropped their target price on Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a report on Thursday, April 23rd. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a report on Thursday. Finally, Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $87.46.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.